Canadian Patient Dosed in Argenx DOK7-CMS Study

Published: 20 November 2024

Our clinical research team at the NeuroMuscular centre of The Ottawa Hospital is excited to share that a Canadian patient affected by DOK-7 Congenital Myasthenic Syndrome (CMS) is the first patient world-wide to be dosed in a global placebo-controlled trial investigating a novel medicine for this neuromuscular condition.

 

Phase 1 Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK-7 CMS

The drug was administered as a part of the global Phase 1 Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants with DOK-7 CMS, sponsored by Argenx. The international Phase 1 study examines the safety and tolerability of ARGX-119 in adult participants with DOK7- CMS, and assesses pharmacokinetics, immunogenicity, and how it may improve the way patients feel and function.

“We are delighted to lead the way in delivering the first dose to a participant in this multi-centre study, and are excited to provide an opportunity for Canadians and patients worldwide with DOK7-CMS to access a potentially disease-modifying therapy” said Lead Investigator, Dr Hanns Lochmüller. “As a Canadian site, we are proud to showcase the efficiency, organization, and trial capacity of Canada’s clinical research centres to conduct neuromuscular clinical trials.”

 

Lochmüller Lab Clinical Research

The study is currently active and recruiting patients. For more information about our clinical trial activities in Ottawa, please visit our clinical research webpage. For a complete list of currently recruiting Canadian neuromuscular clinical trials, please visit the NMD4C Clinical Trials Database.

Clinical trial update - Canadian Patient First in the World to Receive Trial Drug in Argenx DOK7-CMS Study

Read next...

award winners

Celebrating Lab Members’ Recent Research Awards

We are thrilled to celebrate Kelly Ho for receiving first place for her poster presentation at this year’s American Society for Pharmacology and Experimental Therapeutics...
New publication - RTD (2)

Meet The Lochmüller Lab’s Newest Members!

Our research team is growing! We are excited to introduce three new members who have recently joined the Lochmüller lab and several students who will...
McMillan smart study (1)

New Clinical Study Examines Safety and Efficacy of IV Onasemnogene Abeparvovec in Broad SMA Cohort

Pediatric neurologist Dr Hugh McMillan publishes clinical study examining the safety and efficacy of IV onasemnogene abeparvovec in the broadest cohort of SMA patients to...
Text reading: Solve-RD publication: Solve-RD flagship publication: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses. Photos of Dr Kiran Polavarapu, Dr Rachel Thompson, Dr Hanns Lochmüller.

Solve-RD flagship publication in Nature Medicine: Genomic reanalysis of a pan-European rare-disease resource yields new diagnoses

Patients and families with rare disorders often remain without a genetic diagnosis despite modern advances in diagnostic testing. Due to the rarity and global distribution...
New publication: Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis . Author's photos on the right, diagram from paper underneath title.

New Lab Publication Identifies Novel ATP2A2 Variant as Genetic Cause of Dominant Rhabdomyolysis

Rhabdomyolysis is an acute failure of cellular homeostasis characterized by acute skeletal muscle damage triggered by trauma, infection, drugs, or strenuous exercise. Recurrent rhabdomyolysis is...
New lab publication on riboflavin transporter deficiency model

New Publication: Development of a riboflavin-responsive model of riboflavin transporter deficiency in zebrafish

Riboflavin transporter deficiency (RTD) is a rare genetic disorder in children, characterised by progressive sensorimotor and cranial neuronopathy caused by mutations in riboflavin transporter protein-encoding...